Treatment of chemotherapy-Induced Neutropenia in Children with Subcutaneously Administered Recombinant Human Granulocyte Colony-Stimulating Factor

Abstract

Fifty-six children with various malignancies were treated subcutaneously with recombinant human granulocyte colony-stimulating factor (rhG-CSF, KRN 8601) for neutropenia induced by cancer chemotherapy. Patients the first chemotherapy without rhG-CSF (control course). In the second course, rhG-CSF was given once daily, starting 3 days after completion of identical chemotherapy (day 3) and continuing until day 12. At day 12, the white blood counts and neutrophil counts were found to be 6.8 and 30 times higher in the rhG-CSF course than in the control course (P 0001). Nadirs of white blood counts and neutrophils were significantly elevated in the rhG-CSF course (P 003 and. 0001, respectively). rhG-CSF administration shortened the neutropenic period in the majority of patients. Children tolerated the rhG-CSF administration well and we have hereby confirmed that rhG-CSF administration is useful for proceeding with chemotherapy in children with cancer.

Key Words:

• drug-induced neutropenia
• rhG-CSF
• subcutaneous administration